Evidence map›Paper›PMID 36161699›Full record

ArticleThe Kaohsiung journal of medical sciences2022

Long noncoding RNA CDKN2B-AS1 silencing protects against esophageal cancer cell invasion and migration by inactivating the TFAP2A/FSCN1 axis.

Jia-Liang Zhu, Wen-Bo Xue, Zhi-Bin Jiang, Wei Feng, Yi-Cai Liu, Xiong-Ying Nie, Long-Yu Jin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jia-Liang ZhuDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Wen-Bo XueDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Zhi-Bin JiangDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Wei FengDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Yi-Cai LiuDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Xiong-Ying NieDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Long-Yu JinDepartment of Cardiothoracic Surgery, The Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.ORCID https://orcid.org/0000-0003-3274-615X
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer (EC) is the most aggressive malignancy in the gastrointestinal tract. Long noncoding RNA cyclin-dependent kinase inhibitor 2 B antisense RNA 1 (CDKN2B-AS1) is implicated in EC development. However, the specific mechanisms involved remain poorly defined. Therefore, this research aimed to explore the mechanism of action of CDKN2B-AS1 in EC. Quantitative real-time polymerase chain reaction was conducted to measure CDKN2B-AS1 expression in EC cells and western blotting was utilized to evaluate transcription factor AP-2 alpha (TFAP2A) and fascin actin-bundling protein 1 (FSCN1) expression. After gain-of-function and loss-of-function assays, cell proliferation, migration, invasion, apoptosis, and apoptosis-related protein expression were assessed using cell counting kit-8, scratch tests, Transwell assays, flow cytometry, and western blotting, respectively. The binding relationship between CDKN2B-AS1 and TFAP2A was assessed by RNA immunoprecipitation and RNA pull-down assays. The binding relationship between TFAP2A and FSCN1 was evaluated using dual-luciferase reporter and chromatin immunoprecipitation assays. Tumor xenografts from nude mice were used for in vivo verification. CDKN2B-AS1, TFAP2A, and FSCN1 were upregulated in EC cells. Mechanistically, CDKN2B-AS1 transcriptionally activated FSCN1 by recruiting TFAP2A to the FSCN1 promoter. Silencing CDKN2B-AS1 or TFAP2A suppressed EC cell proliferative, migrating, and invasive properties and augmented apoptosis. TFAP2A was bound to CDKN2B-AS1 and the FSCN1 promoter. Overexpression of TFAP2A or FSCN1 abolished the effects of CDKN2B-AS1-silencing on EC cell function. CDKN2B-AS1 silencing curtailed tumorigenesis in nude mice, which was nullified by the upregulation of TFAP2A or FSCN1. Our findings demonstrated the antioncogenic effects of silencing CDKN2B-AS1 in EC through inactivation of the TFAP2A/FSCN1 axis.

Indexed as

Esophageal NeoplasmsMicroRNAsRNA, Long NoncodingAnimalsCarrier ProteinsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudeMicrofilament ProteinsNeoplasm InvasivenessTranscription Factor AP-2Carrier ProteinsFSCN1 protein, humanMicrofilament ProteinsMicroRNAsRNA, Long NoncodingTFAP2A protein, humanTranscription Factor AP-2esophageal cancerfascin actin-bundling protein 1long noncoding RNA CDKN2B-AS1malignant behaviorstranscription factor AP-2 alpha

Identifiers

PMID36161699
PMCPMC11896494
OpenAlexW4297237730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.